V. Stepanenko et al. / Tetrahedron Letters 48 (2007) 5799–5802
5801
Table 2. Reduction of representative halogenated aromatic ketones
with spiroborate with 0.1 equiv of catalyst 1
lington, MA, 2004; (b) Challenger, C. A. Chiral Drugs;
John Wiley & Sons: New york, 2001.
a
b
c
2. Ager, D. J. Chiral Chemicals; Marcel Dekker: New York,
Entry
Substrate
Yield (%)
ee (%)
1
999.
3. Morris, D. J.; Hayes, A. M.; Wills, M. J. Org. Chem. 2006,
1, 7035–7044.
O
O
7
d
1
2
98
84
99 (R)
4
. Schiffers, I.; Rantanen, T.; Schmidt, F.; Bergmans, W.;
Zani, L.; Bolm, C. J. Org. Chem. 2006, 71, 2320–2331.
. (a) Bor e´ n, L.; Martin-Matute, B.; Xu, Y.; Cordova, A.;
B a¨ ckvall, J. E. Chem. Eur. J. 2006, 12, 225–232; (b) Zhu,
D.; Hua, L. J.Org. Chem. 2006, 71, 9484–9486; (c) Zhu,
D.; Yang, Y.; Buynak, J. D.; Hua, L. Org. Biomol. Chem.
2006, 4, 2690–2695.
Cl
Br
5
e
98 (R)
O
Cl
Cl
e
3
4
83
88
95 (S)
6
7
. Fang, T.; Xu, J.; Du, D.-M. Synlett. 2006, 1559–1563.
. For reviews see (a) Glushkov, V. A.; Tolstikov, A. G.
Russ. Chem. Rev. 2004, 73, 581–608; (b) Corey, E. J.
Angew. Chem., Int. Ed. 2002, 41, 1650–1667; (c) Fache, F.;
Schulz, E.; Tomamasino, M.; Lemaire, M. Chem. Rev.
F
F
O
98 (S)
2
000, 100, 2159–2231; (d) Corey, E. J.; Helal, C. J. Angew.
F
Chem., Int. Ed. 1998, 37, 1986–2012; (e) Deloux, L.;
Srebik, M. Chem. Rev. 1993, 93, 763–784; (f) Singh, V. K.
Synthesis 1992, 605–617.
O
O
5
6
97
86
82 (S)
94 (R)
CF3
8. (a) Kanth, J. V. B.; Brown, H. C. Tetrahedron 2002, 58,
069–1074; (b) Liu, D.; Shan, Z.; Zhou, Y.; Wu, X.; Qin,
1
J. Helv. Chim. Acta 2004, 87, 2310–2317; (c) Shan, Z.;
Zhou, Y.; Liu, D.; Ha, W. Synth. React. Inorg. Met.-Org.
Nano-Met. Chem. 2005, 35, 275–279; (d) Yang, S.-D.; Shi,
Y.; Sun, Z.-H.; Zhao, Y.-B.; Liang, Y.-M. Tetrahedron:
Asymmetry 2006, 17, 1895–1900.
. (a) Wang, G.; Hu, J.; Zhao, G. Tetrahedron: Asymmetry
2004, 15, 807–810; (b) Gamble, M. P.; Studle, J. R.; Wills,
M. Tetrahedron Lett. 1992, 37, 2853–2856.
10. (a) Cordes, D. B.; Nguyen, T. M.; Kwong, T. J.; Suri, J.
T.; Luibrand, R. T.; Singaram, B. Eur. J. Org. Chem.
2005, 24, 5289–5295; (b) Cordes, D. B.; Kwong, T. J.;
Morgan, K. A.; Singaram, B. Tetrahedron Lett. 2006, 47,
Cl
a
1
equiv ketone, 0.7 equiv BH
3
ÆDMS and 0.1 equiv catalyst in THF at
9
rt.
b
c
Purified by flash chromatography column or Kugelrohr distillation.
Determined by P NMR of derivate with phosphonate (CDA).
Determined by GC of alcohol on Chiral Column (CP-Chirasil-
DexCB).
Determined by GC of acetyl derivative on Chiral Column.
31
d
e
3
49–351.
Several halogenated ketones were reduced with borane–
DMS in the presence of 10 mol % of catalyst 1 providing
their corresponding alcohols with high enantio-
purity (94–99% ee), except for the highly reactive
1
1
1. Thormeier, S.; Carboni, B.; Kaufmann, D. E. J. Organo-
met. Chem. 2002, 657, 136–145.
2. (a) Stepanenko, V.; Ortiz-Marciales, M.; Correa, W.; De-
Jes u´ s, M.; Espinosa, S.; Ortiz, L. Tetrahedron: Asymmetry
2006, 17, 112–115; (b) Ortiz-Marciales, M.; Stepanenko,
V.; Correa, W.; De Jes u´ s, M.; Espinosa, S. U.S. Patent
Application 11/512,599, August 30, 2006.
2
,2,2,-trifluoroacetophenone (82% ee, entry 5), as illus-
trated in Table 2.
1
1
1
3. Huskens, J.; Reetz, M. T. Eur. J. Org. Chem. 1999, 1775–
In conclusion, a facile and efficient method for the
reduction of aralkyl-, aliphatic- and halogenated aro-
matic ketones in the presence of up to 0.5 mol % cata-
lysts 1 with outstanding enantioselectivities has been
established. Catalyst 1 offer an excellent alternative for
asymmetric reduction of ketones similar in enantioselec-
1
786.
4. Berenguer, R.; Garcia, J.; Vilarrrasa, J. Tetrahedron:
Asymmetry 1991, 5, 165–168.
5. The crystal structure has been deposited at the Cambridge
Crystallographic Data Centre and allocated the deposition
number CCDC 639750. Formula: C H B N O . Unit
1
9
22
1
1
3
tivity to those reported for B-methyl oxazaborolidine
cell parameters: a 8.0330(4), b 9.9264(4), c 20.4313(9),
space group P212121.
7
(
CBS reagent).
1
1
6. Seeger, K.; Heller, G. Z. Kristallogr. 1985, 172, 105–109.
7. Representative procedure. R-(ꢀ)-1-indanol (Table 1, entry
Acknowledgements
5
): To a 100 mL round flask equipped with a septa and
nitrogen flow, 10% of EG-Val borate 1 (0.325 g, 1.0 mmol)
was added. Then, dry THF (30 mL) and BDS complex
(1.0 mL 10 M, 10 mmol) were added to the reaction flask
and the solution was stirred for about 15 min. A solution
of 1-indanone (1.322 g, 10.0 mmol) in dry THF (10 mL)
was added to the reaction mixture for 1 h. The reaction
progress was followed by GC analysis. When the reaction
was complete, the reaction mixture was cooled at 0 ꢁC,
MeOH (20 mL) was added and the mixture was heated in
the rotoevaporator while removing the solvents. The
Financial support by the National Institute of Health
through their MBRS (GM 08216), IMBRE (NC P20
RR-016470) and NSF-ADVANCE (SBE-0123645)
Grants is greatly appreciated. The NIH-IMBRE and
NIH-RISE, NIH-MARC, NSF-AMP undergraduate
student’s support are also gratefully acknowledged.
References and notes
4
concentrated mixture was treated with saturated NH Cl
1
. (a) Silverman, R. B. The Organic Chemistry of Drug
Design and Drug Action; Elsevier Academic Press: Bur-
solution (25 mL) followed by extractions with dichloro-
methane (4 · 20 mL), dried with sodium sulfate and